How The Investment Story Is Shifting For Halozyme Therapeutics (HALO) After Recent Analyst Calls
View original at finance.yahoo.comHow The Investment Story Is Shifting For Halozyme Therapeutics (HALO) After Recent Analyst Calls Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Leerink described the Entyvio ENHANZE deal with Takeda as positive, stressing that management delivered on its commitment to secure a partnership tied to a blockbuster product, even with a lower royalty rate than some past deals
60% confidenceWells Fargo raised Halozyme target to $75 from $65 but kept an Equal Weight rating, emphasizing that progress in next generation subcutaneous technologies remains critical for Halozyme's longer term outlook
60% confidenceAnalysts have shifted their price targets for Halozyme Therapeutics into a $75 to $90 range, even as the model fair value estimate holds steady at $84.5
60% confidenceLeerink pointed out that the Entyvio royalty rate is lower than Halozyme has secured previously and questioned whether payers will support a premium once Entyvio faces biosimilar competition, which could cap the economic upside from that agreement
60% confidenceMorgan Stanley lifted Halozyme price target to $94 from $78 after strong Q4 results, highlighting royalty revenues, expanding ENHANZE partnerships, and progress with Hypercon and Surf Bio assets
60% confidenceTD Cowen moved Halozyme price target to $90 from $79 and pointed to the value of clear multi year frameworks and multiple potential growth drivers when assessing Halozyme within the broader tools and biotech group
60% confidenceBenchmark raised Halozyme price target to $90 from $75, citing strong quarterly results and positive forward guidance as key supports for its constructive view
60% confidence